|Mr. Christopher Michael Cashman||CEO, Pres & Director||N/A||N/A||1957|
|Dr. Scott Braunstein||CEO & Director||15.21k||N/A||1963|
|Mr. Edward F. Smith||VP, CFO, Treasurer & Sec.||501k||N/A||1971|
|Dr. Lorianne K. Masuoka||Chief Medical Officer||501k||N/A||1961|
|Ms. Lisa M. Caperelli||Exec. Director of Investor & Strategic Relations||N/A||N/A||N/A|
Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate exhibits anti-seizure, anti-depression, and anti-anxiety actions through its effects on synaptic and extrasynaptic GABAA receptors. It is also developing ganaxolone for cyclin-ependent kinase-like 5 deficiency disorder, PCDH19-related epilepsy, postpartum depression, refractory status epilepticus, and other indications. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license and supply agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.
Marinus Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 5; Compensation: 6.